FDA Extends Nexplanon Use - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Extends Nexplanon Use

US study data showed zero pregnancies in years 4 and 5 of etonogestrel implant use.

  • By

  • Kathryn Wighton

  • January 20, 2026

  • 3 min

Share

Clinical Scorecard: FDA Extends Nexplanon Use

At a Glance

CategoryDetail
ConditionPregnancy prevention
Key MechanismsEtonogestrel implant providing long-acting contraception
Target PopulationWomen of reproductive potential, ages 18-35, with varying BMI
Care SettingCertified healthcare providers and pharmacies

Key Highlights

  • Nexplanon use extended from 3 years to 5 years for pregnancy prevention
  • Zero pregnancies reported during years 4 and 5 of use
  • No new safety findings during extended use
  • Changes in menstrual bleeding patterns are common adverse reactions
  • REMS program implemented to mitigate insertion and removal complications

Guideline-Based Recommendations

Diagnosis

  • Assess reproductive potential and suitability for long-acting contraception

Management

  • Provide Nexplanon as a contraceptive option for up to 5 years

Monitoring & Follow-up

  • Monitor for changes in menstrual bleeding patterns and other adverse reactions

Risks

  • Potential complications from improper insertion and removal

Patient & Prescribing Data

Women aged 18-35, including those with a BMI range from 17.2 to 64.3 kg/m2

Effective contraception with no pregnancies reported during extended use

Clinical Best Practices

  • Ensure proper training for healthcare providers on insertion and removal
  • Implement REMS to enhance patient safety
  • Educate patients on potential menstrual changes and adverse reactions

Related Resources & Content

Original Source(s)

FDA Extends Nexplanon Use

  • by Kathryn Wighton

  • January 20, 2026

Related Content

Birthweight, Childhood BMI: What Drives the Link?

Mendelian randomization analyses linked higher birthweight with greater mid-childhood height but the connection could reflect genetic factors related to skeletal growth.

Medical Oddities: Something Viral is Lurking in the Dust

Everyday things like yawns, tea, dust, and kimchi suddenly look medically important.

ACP Ranks Obesity Drug Options

A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.